Nabumetone use and risk of acute pancreatitis in a case-control study

Hung, Shih Chang; Liao, Kuan Fu; Hung, Hung Chang; Lin, Cheng Li; Lai, Shih Wei; Lin, Chi-Yi

doi:10.1016/j.pan.2016.03.003

Cited by 14 publications

(9 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Second, the same limitations may result in a differential misclassification of comorbidities based on ICD‐9 codes. However, the diagnostic accuracy of the studied comorbidities has been well examined in previous studies . Third, the underlying causes of acute pancreatitis were not recorded due to the same limitations, making it difficult to assess how many patients with idiopathic acute pancreatitis might be potentially associated with simvastatin use, but this cause may be overlooked by clinicians.…”

Section: Discussionmentioning

confidence: 99%

“…However, the diagnostic accuracy of the studied comorbidities has been well examined in previous studies. [16][17][18][19][20][21][22][23][24]30 Third, the underlying causes of acute pancreatitis were not recorded due to the same limitations, making it difficult to assess how many patients with idiopathic acute pancreatitis might be potentially associated with simvastatin use, but this cause may be overlooked by clinicians. Fourth, we cannot exclude the possibility that simvastatin users might simultaneously be taking other medications that can induce acute pancreatitis.…”

Section: Discussionmentioning

confidence: 99%

“…Comorbidities prior to the index date that are potentially related to acute pancreatitis include alcohol‐related diseases (ICD‐9 codes 291, 303, 305.00, 305.01, 305.02, 305.03, 571.0‐571.3, 790.3, and V11.3), biliary stone (ICD‐9 code 574), cardiovascular diseases including coronary artery disease, heart failure, cerebrovascular disease, and peripheral atherosclerosis (ICD‐9 codes 410‐414, 428, 430‐438, and 440‐448), chronic kidney disease (ICD‐9 codes 585‐586 and 588.8‐588.9), chronic obstructive pulmonary disease (ICD‐9 codes 491, 492, 493, and 496), hepatitis B infection (ICD‐9 codes V02.61, 070.20, 070.22, 070.30, and 070.32), hepatitis C infection (ICD‐9 codes V02.62, 070.41, 070.44, 070.51 and 070.54), hyperparathyroidism (ICD‐9 code 252.0), and hypertriglyceridemia (ICD‐9 code 272.1, 272.2, and 272.4). Based on ICD‐9 codes, the diagnosis accuracy of included comorbidities has been well examined in previous studies …”

Section: Methodsmentioning

confidence: 99%

“…Based on ICD-9 codes, the diagnosis accuracy of included comorbidities has been well examined in previous studies. [16][17][18][19][20][21][22][23][24] Definition of Simvastatin Use The last remaining simvastatin tablet for each subject can be calculated based on prescription history. Consistent with previous studies, 20,25-29 recent use of simvastatin was defined as subjects whose last remaining simvastatin tablet was noted ࣘ7 days prior to the date of acute pancreatitis diagnosis or having tablets at the date of diagnosis.…”

Section: Potential Comorbidities Associated With Acute Pancreatitismentioning

confidence: 99%

See 3 more Smart Citations

Use of Simvastatin and Risk of Acute Pancreatitis: A Nationwide Case-Control Study in Taiwan

Lin¹,

Liao

Lin

et al. 2017

The Journal of Clinical Pharmacology

Self Cite

View full text Add to dashboard Cite

The correlation between simvastatin use and acute pancreatitis is explored. A case-control study was conducted to analyze claim data from the Taiwan National Health Insurance Program. The case group comprising a total of 3882 subjects aged 20 to 84 years with their first acute pancreatitis episode occurring between 1998 and 2011 formed the case group, against 3790 randomly selected controls matched for sex, age, comorbidities, and index year of acute pancreatitis diagnosis. Recent use of simvastatin was defined as subjects whose last remaining simvastatin tablet was noted ≤7 days before the date of acute pancreatitis diagnosis. Remote use of simvastatin was defined as subjects whose last remaining 1 tablet for simvastatin was noted >7 days before the date of acute pancreatitis diagnosis. Never use of simvastatin was defined as subjects who had never been prescribed simvastatin. A multivariable unconditional logistic regression model was used to estimate the odds ratio and 95%CI to explore the correlation between simvastatin use and acute pancreatitis. After adjustment for confounders, multivariable logistic regression analysis revealed that the adjusted odds ratio of acute pancreatitis was 1.3 for subjects with recent use of simvastatin (95%CI 1.02, 1.73), when compared with those with never use of simvastatin. The crude odds ratio decreased to 1.1 for those with remote use of simvastatin (95%CI 0.93, 1.34) but without statistical significance. Recent use of simvastatin is associated with acute pancreatitis. Clinicians should consider the possibility of simvastatin-associated acute pancreatitis for patients presenting for acute pancreatitis without known cause.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Potential Comorbidities Associated With Acute Pancreatitismentioning

confidence: 99%

See 2 more Smart Citations

Use of Simvastatin and Risk of Acute Pancreatitis: A Nationwide Case-Control Study in Taiwan

Lin¹,

Liao

Lin

et al. 2017

The Journal of Clinical Pharmacology

Self Cite

View full text Add to dashboard Cite

show abstract

“…All comorbidities were diagnosed with ICD-9 codes. The accuracy of these codes has been examined in previous studies (Lai et al, 2013a,b, 2014a,b, 2017; Hung et al, 2016; Lai, 2016; Lin et al, 2016a, 2016b; Shen et al, 2016; Hsu et al, 2017; Liao et al, 2017a,b). …”

Section: Methodsmentioning

confidence: 99%

Correlation of Proton Pump Inhibitors with Pulmonary Tuberculosis: A Case-Control Study in Taiwan

et al. 2017

Self Cite

View full text Add to dashboard Cite

Background and Objectives: Although the relationship between the use of proton pump inhibitors (PPIs) and pulmonary tuberculosis (TB) in Taiwan published in 2014. Due to just only one article and not enough comprehensively, we explore this issue.Methods: We conducted a population-based case-control study to identify 9,422 subjects aged 20 years or older with newly diagnosed pulmonary TB in 2000–2013 as test cases. We then randomly selected 9,422 subjects aged 20 years or older without pulmonary TB as controls. Both cases and controls were matched in terms of sex, age, and comorbidities. Use of PPIs were defined as subjects who had had at least one prescription for these medications before the index date. No use was defined as subjects who had never had a prescription for PPIs before the index date. The odds ratio (OR) and 95% confidence interval (CI) for pulmonary TB associated with PPI use was estimated using the logistic regression model.Results: The OR of pulmonary TB was 1.31 for subjects who had used PPIs (95% CI 1.22, 1.41) compared with those with no use of the medications. Sub-analysis revealed the OR of pulmonary TB in subjects using PPI per increasing microgram was 1.25 (95% CI 1.19, 1.30).Conclusions: PPI use is associated with a 1.3-fold increase in odds of developing pulmonary TB in Taiwan. There is a dose-related response between PPI use and pulmonary TB.

show abstract

Association of use of selective serotonin reuptake inhibitors with risk of acute pancreatitis: a case-control study in Taiwan

Lin

Liao

Chang

et al. 2017

Eur J Clin Pharmacol

View full text Add to dashboard Cite

show abstract

Nabumetone use and risk of acute pancreatitis in a case-control study

Cited by 14 publications

References 31 publications

Use of Simvastatin and Risk of Acute Pancreatitis: A Nationwide Case-Control Study in Taiwan

Use of Simvastatin and Risk of Acute Pancreatitis: A Nationwide Case-Control Study in Taiwan

Correlation of Proton Pump Inhibitors with Pulmonary Tuberculosis: A Case-Control Study in Taiwan

Association of use of selective serotonin reuptake inhibitors with risk of acute pancreatitis: a case-control study in Taiwan

Contact Info

Product

Resources

About